



Accredited Activity Disclosure Statement

The Basic Antimicrobial Stewardship Training Program – 2019 January 1, 2019 to December 31, 2022

Pharmacist Accreditation

Making a Difference in Infectious Diseases (MAD-ID) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. MAD-ID designates this enduring activity for a maximum of 26.00 contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Physician Accreditation

MAD-ID is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MAD-ID designates this enduring activity for a maximum of 20.00 *AMA PRA Category 1 Credits*[™]. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

In accord with the disclosure policy of MAD-ID and the *Standards for Integrity and Independence Accreditation Criteria* adopted by the ACPE and ACCME, course planners, speakers, and content reviewers have been asked to disclose any relationship they have with companies producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. In addition, faculty have been asked to list any off-label uses of pharmaceuticals and/or devices for investigational or non-FDA approved purposes that they plan to discuss.

Such disclosure is not intended to suggest or condone bias in any presentation, but is solicited to provide the course director and participants with information that might be of potential importance to their evaluation of a given presentation.

The following planners, speakers, and content reviewers have reported financial relationships (relevant to the content of the activity) with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients:

NAME	COMPANY	RELATIONSHIP
<i>Course Planners:</i>		
John A. Bosso, PharmD, FCCP, FIDSA	Achaogen Allergan Curetis The Medicines Company Melinta Motif Merck Nabriva Roche Diagnostics Shinogi Tetraphase	Advisory Committee/Board Speaker and Advisory Committee/Board Advisory Committee/Board Research Support Advisory Committee/Board Advisory Committee/Board Research Support Advisory Committee/Board Advisory Committee/Board Advisory Committee/Board Advisory Committee/Board
Susan L. Davis, PharmD	Achaogen Melinta Merck Nabriva	Advisory Committee/Board Advisory Committee/Board Research Support Advisory Committee/Board



NAME	COMPANY	RELATIONSHIP
Course Planners:		
Thomas M. File, MD, MSc, MACP, FIDSA, FCCP	Merck	Advisory Committee/Board
	MotifBio	Advisory Committee/Board
	Nabriva	Advisory Committee/Board
	Paratek	Advisory Committee/Board
	Shionogi	Advisory Committee/Board
Michael Rybak, PharmD, MPH, PhD, FCCP, FIDP	Accelerate	Consultant and Research Support
	Allergan	Consultant, Speaker and Research Support
	Ampliphi	Consultant and Research Support
	Bayer	Consultant, Speaker and Research Support
	Contrafect	Consultant and Research Support
	Melinta	Consultant, Speaker and Research Support
	Merck	Consultant, Speaker and Research Support
	Nabriva	Consultant
	Paratek	Consultant
	Shionogi	Consultant and Research Support
Tetraphase	Consultant	
Kerry L. LaPlante, PharmD, FCCP, FIDSA	Allergan	Advisory Committee/Board
	Merck	Research Support
	Pfizer	Research Support
	The Medicines Company	Research Support
	Melinta	Advisory Committee/Board
	Nabriva Therapeutics	Advisory Committee/Board
	Paratek	Advisory Committee/Board
	Tetraphase	Advisory Committee/Board

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no financial relationships related to the content of this activity.

This activity is supported by educational grants from bioMérieux, Inc., Accelerate Diagnostics, Inc., and Achaogen